LONDON, July 28, 2020 /PRNewswire/ --
- Davidson Kempner European Partners, LLP is the sub-adviser to Davidson Kempner Capital Management LP which acts as the discretionary investment manager to various funds which represent 5.1% of the share capital of QIAGEN N.V. (the "Company")
- Davidson Kempner believes the standalone fair value for the Company to be €48-52 per share
- Davidson Kempner will not be tendering its shares and fully expects the current offer to fail
- Davidson Kempner has launched a website containing supporting information and evidence: https://unlockthevalueofqiagen.com/
For media enquiries:
Greenbrook
Andrew Honnor, Rob White, Fanni Bodri
Email: [email protected]
Tel: +44 (0) 20 7952-2000
SOURCE Davidson Kempner
"current" - Google News
July 28, 2020 at 10:39PM
https://ift.tt/30Q5FhA
Davidson Kempner Expects Thermo Fisher Scientific's Current Offer for QIAGEN NV to Fail - PRNewswire
"current" - Google News
https://ift.tt/3b2HZto
https://ift.tt/3c3RoCk
Bagikan Berita Ini
0 Response to "Davidson Kempner Expects Thermo Fisher Scientific's Current Offer for QIAGEN NV to Fail - PRNewswire"
Post a Comment